WO2005003097A1 - Cis-2,4,5-triaryl-imidazolines - Google Patents
Cis-2,4,5-triaryl-imidazolines Download PDFInfo
- Publication number
- WO2005003097A1 WO2005003097A1 PCT/EP2004/006176 EP2004006176W WO2005003097A1 WO 2005003097 A1 WO2005003097 A1 WO 2005003097A1 EP 2004006176 W EP2004006176 W EP 2004006176W WO 2005003097 A1 WO2005003097 A1 WO 2005003097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- trifluoromethyl
- bis
- chloro
- dihydro
- Prior art date
Links
- 0 CC=C(C)C(C(N(*)C1c2ccc(*)cc2)=NC1c1ccc(*)cc1)=CC=CC(F)(F)F Chemical compound CC=C(C)C(C(N(*)C1c2ccc(*)cc2)=NC1c1ccc(*)cc1)=CC=CC(F)(F)F 0.000 description 21
- ZPLQIVWVSAFPJR-UHFFFAOYSA-N Cc1ccc(C(C2c(cc3)ccc3Cl)N=C(c(ccc(C(F)(F)F)c3)c3OCC(C=C)=C)N2C(N2CCN(CC(NC3CC3)=O)CC2)=O)cc1 Chemical compound Cc1ccc(C(C2c(cc3)ccc3Cl)N=C(c(ccc(C(F)(F)F)c3)c3OCC(C=C)=C)N2C(N2CCN(CC(NC3CC3)=O)CC2)=O)cc1 ZPLQIVWVSAFPJR-UHFFFAOYSA-N 0.000 description 1
- QJQZRLXDLORINA-UHFFFAOYSA-N OCCC1CCCCC1 Chemical compound OCCC1CCCCC1 QJQZRLXDLORINA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Definitions
- Ri 8 is selected from the group consisting of lower alkoxy, cyano, trifluoromethyl, heterocycle and hydroxyl;
- R is selected from the group consisting of
- R 5 is selected from the group consisting of oxo, heteroaryl, aryl substituted by a substituent selected from lower alkoxy and fluoro,
- N-lower alkyl substituted by R ⁇ 8 heterocycle and heterocycle substituted by one or two substituents selected from the group consisting of hydroxy, alkoxy, trifluoromethyl, C(O)-lower alkyl, C(O)-NH 2 , C(O)-N-lower alkyl, lower alkyl substituted by hydroxy and oxo;
- R17 is selected from the group consisting of
- heterocycle elected from the group consisting of
- Xi and X 2 are chloro, X 3 is ethoxy or sopropoxy, the trifluoromethyl group is meta to the imidazoline ring, and R is C(O)- ?iperazine substituted by R 5 .
- “Pharmaceutically acceptable salt” refers to conventional acid-addition salts or base- addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
- Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
- the compound of formula 9 can react with an appropriately protected piperidine to afford a compound of formula 15 after deprotection.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002528119A CA2528119A1 (fr) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triarylimidazolines |
AU2004254187A AU2004254187A1 (en) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaryl-imidazolines |
JP2006515856A JP2006527712A (ja) | 2003-06-17 | 2004-06-08 | シス−2,4,5−トリアリール−イミダゾリン |
EP04739704A EP1638942A1 (fr) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaryl-imidazolines |
BRPI0411841-3A BRPI0411841A (pt) | 2003-06-17 | 2004-06-08 | cis-2,4,5-triaril-imidazolinas |
MXPA05013279A MXPA05013279A (es) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaril-imidazolinas. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47935103P | 2003-06-17 | 2003-06-17 | |
US60/479,351 | 2003-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005003097A1 true WO2005003097A1 (fr) | 2005-01-13 |
Family
ID=33563793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/006176 WO2005003097A1 (fr) | 2003-06-17 | 2004-06-08 | Cis-2,4,5-triaryl-imidazolines |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1638942A1 (fr) |
JP (1) | JP2006527712A (fr) |
KR (1) | KR100768021B1 (fr) |
CN (1) | CN100465163C (fr) |
AR (1) | AR044703A1 (fr) |
AU (1) | AU2004254187A1 (fr) |
BR (1) | BRPI0411841A (fr) |
CA (1) | CA2528119A1 (fr) |
CL (1) | CL2004001484A1 (fr) |
MX (1) | MXPA05013279A (fr) |
RU (1) | RU2319696C2 (fr) |
TW (1) | TW200510387A (fr) |
WO (1) | WO2005003097A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072655A1 (fr) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Dérivés d'imidazothiazole |
JP2008533073A (ja) * | 2005-03-16 | 2008-08-21 | エフ.ホフマン−ラ ロシュ アーゲー | シス−2,4,5−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用 |
WO2009151069A1 (fr) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | Dérivé d’imidazothiazole ayant une structure cyclique de 4,7-diazaspiro[2.5]octane |
WO2010082612A1 (fr) | 2009-01-16 | 2010-07-22 | 第一三共株式会社 | Dérivé d'imidazothiazole comprenant une structure de noyau proline |
JP4870778B2 (ja) * | 2005-12-01 | 2012-02-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるp53およびmdm2タンパク質間の相互作用の阻害剤としての2,4,5−トリフェニルイミダゾリン誘導体 |
US8114095B2 (en) * | 2006-11-10 | 2012-02-14 | Bausch & Lomb Incorporated | Intraocular lens injection apparatus and method |
WO2013054153A1 (fr) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composés de nutline pour une utilisation dans le traitement de l'hypertension artérielle pulmonaire |
WO2017201449A1 (fr) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Conjugués anticorps-protac et procédés d'utilisation |
WO2023056069A1 (fr) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation |
RU2809688C1 (ru) * | 2022-10-03 | 2023-12-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Новые азотзамещенные 2,4,5-три(метоксифенил) цис-имидазолины, способ их получения и применения |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
IT1396520B1 (it) | 2009-12-10 | 2012-12-14 | Nuovo Pignone Spa | Accoppiamento per bilanciamento rotore |
CA3120514A1 (fr) * | 2018-11-20 | 2020-05-28 | Sironax Ltd | Urees cycliques |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0433682A2 (fr) * | 1989-11-22 | 1991-06-26 | Marion Merrell Dow Inc. | Utilisation de 2,4,5-tri(4-méthoxyphényl)-4,5-dihydroimidazole pour le traitement du cancer |
WO2002020017A2 (fr) * | 2000-09-04 | 2002-03-14 | Merck Patent Gmbh | Utilisation de l'ectoine ou de derives de l'ectoine pour la stabilisation du p53 |
WO2003051359A1 (fr) * | 2001-12-18 | 2003-06-26 | F.Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazolines et leurs utilisations dans le traitement des tumeurs |
-
2004
- 2004-06-08 JP JP2006515856A patent/JP2006527712A/ja not_active Ceased
- 2004-06-08 MX MXPA05013279A patent/MXPA05013279A/es unknown
- 2004-06-08 RU RU2006100730/04A patent/RU2319696C2/ru not_active IP Right Cessation
- 2004-06-08 BR BRPI0411841-3A patent/BRPI0411841A/pt not_active IP Right Cessation
- 2004-06-08 WO PCT/EP2004/006176 patent/WO2005003097A1/fr active Application Filing
- 2004-06-08 EP EP04739704A patent/EP1638942A1/fr not_active Withdrawn
- 2004-06-08 KR KR1020057024295A patent/KR100768021B1/ko not_active IP Right Cessation
- 2004-06-08 AU AU2004254187A patent/AU2004254187A1/en not_active Abandoned
- 2004-06-08 CN CNB2004800170350A patent/CN100465163C/zh not_active Expired - Fee Related
- 2004-06-08 CA CA002528119A patent/CA2528119A1/fr not_active Abandoned
- 2004-06-11 TW TW093116988A patent/TW200510387A/zh unknown
- 2004-06-15 AR ARP040102068A patent/AR044703A1/es not_active Application Discontinuation
- 2004-06-15 CL CL200401484A patent/CL2004001484A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0433682A2 (fr) * | 1989-11-22 | 1991-06-26 | Marion Merrell Dow Inc. | Utilisation de 2,4,5-tri(4-méthoxyphényl)-4,5-dihydroimidazole pour le traitement du cancer |
WO2002020017A2 (fr) * | 2000-09-04 | 2002-03-14 | Merck Patent Gmbh | Utilisation de l'ectoine ou de derives de l'ectoine pour la stabilisation du p53 |
WO2003051359A1 (fr) * | 2001-12-18 | 2003-06-26 | F.Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazolines et leurs utilisations dans le traitement des tumeurs |
Non-Patent Citations (1)
Title |
---|
SEUNG HOON CHEON ET AL: "Synthesis and Structure-Activity Relationship Studies of 2,3-Dihydroimidazo[2,1-a]isoquinoline Analogs as Antitumor Agents", ARCHIVES OF PHARMACAL RESEARCH, vol. 20, no. 2, 1997, NATIONAL FISHERIES UNIVERSITY, PUSAN, KOREA, pages 138 - 143, XP009036613 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008533073A (ja) * | 2005-03-16 | 2008-08-21 | エフ.ホフマン−ラ ロシュ アーゲー | シス−2,4,5−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用 |
JP4870778B2 (ja) * | 2005-12-01 | 2012-02-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるp53およびmdm2タンパク質間の相互作用の阻害剤としての2,4,5−トリフェニルイミダゾリン誘導体 |
US8114095B2 (en) * | 2006-11-10 | 2012-02-14 | Bausch & Lomb Incorporated | Intraocular lens injection apparatus and method |
WO2008072655A1 (fr) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Dérivés d'imidazothiazole |
WO2009151069A1 (fr) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | Dérivé d’imidazothiazole ayant une structure cyclique de 4,7-diazaspiro[2.5]octane |
WO2010082612A1 (fr) | 2009-01-16 | 2010-07-22 | 第一三共株式会社 | Dérivé d'imidazothiazole comprenant une structure de noyau proline |
US8404691B2 (en) | 2009-01-16 | 2013-03-26 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives having proline ring structure |
WO2013054153A1 (fr) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composés de nutline pour une utilisation dans le traitement de l'hypertension artérielle pulmonaire |
WO2017201449A1 (fr) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Conjugués anticorps-protac et procédés d'utilisation |
WO2023056069A1 (fr) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation |
RU2809688C1 (ru) * | 2022-10-03 | 2023-12-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Новые азотзамещенные 2,4,5-три(метоксифенил) цис-имидазолины, способ их получения и применения |
Also Published As
Publication number | Publication date |
---|---|
MXPA05013279A (es) | 2006-03-09 |
CL2004001484A1 (es) | 2005-05-27 |
CN100465163C (zh) | 2009-03-04 |
KR100768021B1 (ko) | 2007-10-18 |
CN1809538A (zh) | 2006-07-26 |
RU2319696C2 (ru) | 2008-03-20 |
JP2006527712A (ja) | 2006-12-07 |
TW200510387A (en) | 2005-03-16 |
EP1638942A1 (fr) | 2006-03-29 |
RU2006100730A (ru) | 2006-08-10 |
AU2004254187A1 (en) | 2005-01-13 |
CA2528119A1 (fr) | 2005-01-13 |
AR044703A1 (es) | 2005-09-21 |
KR20060021902A (ko) | 2006-03-08 |
BRPI0411841A (pt) | 2006-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7425638B2 (en) | Cis-imidazolines | |
JP5324586B2 (ja) | キラルシス−イミダゾリン | |
US7705007B2 (en) | Cis-imidazolines | |
KR100855929B1 (ko) | 신규 시스-이미다졸린 | |
KR101139263B1 (ko) | 시스-2,4,5-트리아릴-이미다졸린 및 항암 약제로서의그의 용도 | |
EP1960368B1 (fr) | Derives de 2,4,5-triphenyl imidazoline en tant qu'inhibiteurs de l'interaction entre les proteines p53 et mdm2, utilises en tant qu'agents anticancereux | |
WO2005003097A1 (fr) | Cis-2,4,5-triaryl-imidazolines | |
JPH09500124A (ja) | 5‐ht1a受容体拮抗物質としてのn‐(ピペリジニル‐1‐アルキル)‐置換シクロヘキサンカルボン酸アミド | |
WO2014082889A1 (fr) | Nouvelles imidazolines utilisées en tant que doubles inhibiteurs de mdm2 et mdmx |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004739704 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2528119 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/013279 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3409/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004254187 Country of ref document: AU Ref document number: 2006515856 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057024295 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048170350 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004254187 Country of ref document: AU Date of ref document: 20040608 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004254187 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006100730 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057024295 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739704 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0411841 Country of ref document: BR |